Catalyst Pharmaceuticals (CPRX) Net Margin (2018 - 2026)

Catalyst Pharmaceuticals has reported Net Margin for 9 years, with the latest figure at 42.66% in Q1 2026.

• For the quarter ending Q1 2026, Net Margin rose 254.0% year-over-year to 42.66%; the trailing twelve-month figure through Mar 2026 stood at 35.94% (up 80.0% YoY), and the FY2025 full-year result was 35.24%, up 383.0% from the prior year.
• Net Margin for Q1 2026 stood at 42.66%, up from 30.1% in the prior quarter.
• The five-year high for Net Margin was 56.38% in Q4 2022, with the low at 29.96% in Q3 2023.
• Historically, Net Margin has averaged 31.37% across 5 years, with a median of 34.64% in 2023.
• Annual changes were most pronounced in 2023 — Net Margin tumbled 6970 bps — and 2024, when it surged 6406 bps.
• Catalyst Pharmaceuticals' Net Margin stood at 56.38% in 2022, then plunged by 73 bps to 15.41% in 2023, then soared by 113 bps to 32.78% in 2024, then decreased by 8 bps to 30.1% in 2025, then surged by 42 bps to 42.66% in 2026.
• The last three Net Margin figures came in at 42.66% (Q1 2026), 30.1% (Q4 2025), and 35.57% (Q3 2025), per Business Quant data.